Vir Biotechnology, Inc. License Agreements
15 Contracts & Agreements
- License Agreement between (Filed With SEC on November 4, 2024)
- Third Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated March 1, 2021 (Filed With SEC on May 6, 2021)
- Amendment 1 to Patent License Agreement dated as of March 25, 2020, between the Company and Xencor, Inc., dated February 23, 2021 (Filed With SEC on May 6, 2021)
- Amendment 1 to Patent License Agreement dated as of August 15, 2019, between the Company and Xencor, Inc., dated February 23, 2021 (Filed With SEC on May 6, 2021)
- Second Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated September 28, 2020 (Filed With SEC on February 25, 2021)
- Amendment No. 1 to License Agreement between the Company and MedImmune, LLC, dated September 1, 2020 (Filed With SEC on February 25, 2021)
- Patent License Agreement between the Registrant and Xencor, Inc., dated August 15, 2019 (Filed With SEC on September 3, 2019)
- Amendment to Exclusive License Agreement between the Registrant and The Rockefeller University, dated May 17, 2019 (Filed With SEC on September 3, 2019)
- Exclusive License Agreement between the Registrant and The Rockefeller University, dated July 31, 2018 (Filed With SEC on September 3, 2019)
- Amendment to License Agreement between the Registrant (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated February 10, 2012 (Filed With SEC on September 3, 2019)
- Exclusive License Agreement between the Registrant (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated December 16, 2011 (Filed With SEC on September 3, 2019)
- Amendment to Amended and Restated Exclusive License Agreement between the Registrant (as successor in interest to Humabs BioMed SA (f/k/a Humabs Holding GmbH)) and the Institute... (Filed With SEC on September 3, 2019)
- Amended and Restated Exclusive License Agreement between the Registrant (as successor in interest to Humabs BioMed SA (f/k/a Humabs Holding GmbH)) and the Institute for Research... (Filed With SEC on September 3, 2019)
- Second Revised and Restated Master License Agreement between the Registrant and Oregon Health & Science University, dated August 27, 2019 (Filed With SEC on September 3, 2019)
- License Agreement between the Registrant and MedImmune, LLC, dated September 7, 2018 (Filed With SEC on September 3, 2019)
